Crescent Biopharma officer plans sale of 8,387 shares

Officer Jonathan McNeill files a Rule 144 notice to resell Crescent Biopharma ordinary shares recently acquired through RSU vesting, with prior share sales also disclosed.

Available on EDGAR 09/17/2026 - 04:33 PM EDT Accepted by SEC EDGAR 09/17/2026 - 04:32 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

CRESCENT BIOPHARMA, INC. (CBIO) is the issuer for a notice in which officer Jonathan McNeill files to rely on Rule 144 for sales of the company’s ordinary shares. The notice describes a planned sale tied to 8,387 ordinary shares acquired through restricted stock unit vesting on September 17, 2026 for services rendered.

The filing also lists prior sales of Crescent Biopharma ordinary shares by McNeill in the preceding three months, and identifies Morgan Stanley Smith Barney LLC Executive Financial Services, with a New York address, in connection with the ordinary shares and Nasdaq listing information.

Key Figures

Shares associated with RSU vesting: 8,387 ordinary shares Shares sold June 22, 2026: 20,549 ordinary shares Proceeds from June 22, 2026 sale: $369,768.98 +2 more

5 metrics

Shares associated with RSU vesting 8,387 ordinary shares Restricted Stock Unit Vesting on September 17, 2026 for services rendered

Shares sold June 22, 2026 20,549 ordinary shares Sale of Crescent Biopharma ordinary shares on June 22, 2026

Proceeds from June 22, 2026 sale $369,768.98 Aggregate sale price for 20,549 ordinary shares on June 22, 2026

Shares sold September 16, 2026 731 ordinary shares Sale of Crescent Biopharma ordinary shares on September 16, 2026

Proceeds from September 16, 2026 sale $13,083.36 Aggregate sale price for 731 ordinary shares on September 16, 2026

Key Terms

Rule 144, Restricted Stock Unit Vesting, services rendered, Ordinary Shares

4 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144"

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Restricted Stock Unit Vesting financial

"Ordinary Shares | 09/17/2026 | Restricted Stock Unit Vesting | Issuer"

services rendered financial

"8387 | 09/17/2026 | Services rendered"

Ordinary Shares financial

"Ordinary Shares | Morgan Stanley Smith Barney LLC Executive Financial Services"

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing disclose for Crescent Biopharma (CBIO)?

The filing states that officer Jonathan McNeill intends to rely on Rule 144 to resell Crescent Biopharma ordinary shares, including 8,387 shares acquired through restricted stock unit vesting on September 17, 2026, which were received for services rendered.

How many Crescent Biopharma (CBIO) shares are tied to the new Rule 144 notice?

The notice describes 8,387 ordinary shares of Crescent Biopharma associated with restricted stock unit vesting on September 17, 2026, received as compensation for services rendered.

What prior sales of CBIO shares by Jonathan McNeill are reported?

The filing reports that Jonathan McNeill sold 20,549 ordinary shares on June 22, 2026 for $369,768.98 and 731 ordinary shares on September 16, 2026 for $13,083.36, both involving Crescent Biopharma ordinary shares.

How were the new Crescent Biopharma (CBIO) shares acquired by Jonathan McNeill?

The 8,387 ordinary shares covered in the notice were acquired through Restricted Stock Unit Vesting on September 17, 2026, with the filing describing the consideration as services rendered to the issuer.

Which intermediary is listed in connection with the CBIO ordinary shares in this filing?

The filing lists Morgan Stanley Smith Barney LLC Executive Financial Services with a New York address in connection with Crescent Biopharma ordinary shares and notes the Nasdaq listing information.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001824673
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Crescent Biopharma, Inc.
SEC File Number	001-36177
Address of Issuer	300 5th Ave Waltham MASSACHUSETTS 02451
Phone	6174305595
Name of Person for Whose Account the Securities are To Be Sold	Jonathan McNeill
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Ordinary Shares	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	4415	75849.7	37143940	09/18/2026	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Ordinary Shares	09/17/2026	Restricted Stock Unit Vesting	Issuer			8387	09/17/2026	Services rendered

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Jonathan McNeill 300 5th Ave Waltham MA 02451	Ordinary Shares	06/22/2026	20549	369768.98
Jonathan McNeill 300 5th Ave Waltham MA 02451	Ordinary Shares	09/16/2026	731	13083.36

144: Remarks and Signature

Remarks
Date of Notice	09/17/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	02/25/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Barbara Bispham Hale, as Attorney-in-Fact for Jonathan McNeill
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)